Two-year experience with buprenorphine-naloxone (suboxone) for maintenance treatment of opioid dependence within a private practice setting

Journal of Addiction Medicine

Volumn 1, Issue 2, 2007, Pages 104-110

  Finch, James W ^a,b   Kamien, Jonathan B ^a   Amass, Leslie ^a  

^a BioPsych Consulting   (United States)

^b not available   (United States)

Author keywords

Buprenorphine; Office based addiction treatment; Suboxone

Indexed keywords

EID: 43449112838     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31809b5df2     Document Type: Article

References (30)

1. Carrieri MP, Amass L, Lucas G, et al. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43 (Suppl 4):S197-S215.
2. Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25: 91-103.
3. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003 70 (Suppl 2):S59-S77.
4. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict. 2004;13 (Suppl 1):S17-S28.
5. Lintzeris N, Ritter A, Panjari M, et al. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict. 2004;13 (Suppl 1):S29-S41.
6. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70 (Suppl 2):S39-S47.
7. Mendelson J, Jones RT, Fernandez I, et al. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther. 1996; 60:105-114.
8. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
9. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphinenaloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75-78.
10. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001;154:230-242.
11. Drug Addiction Treatment Act of 2000, Pub. L. No. 106-310. October 17, 2000.
12. Boatwright DE. Buprenorphine and addiction: challenges for the pharmacist. J Am Pharm Assoc. 2002;42:432-438.
13. Schuster CR.. Postmarketing surveillance for Suboxone and Subutex diversion. In: Harris LS, ed. Problems of Drug Dependence 2005: Proceedings of the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute on Drug Abuse Research Monograph Series
14. Rockville, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2006.
15. Colameco S, Armando J, Trotz C. Opiate dependence treatment with buprenorphine: one year's experience in a family practice setting. J Addict Dis. 2005;24:25-32.
16. Collins ED, Horton T, Reinke K, et al. Using buprenorphine to facilitate entry to residential therapeutic community rehabilitation. J Subst Abuse Treat. 2007;32:167-175.
17. Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network Field Experience. Am J Addict. 2004 13 (Suppl 1):S42-S66.
18. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090-1100.
19. Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5:146-150.
20. Brigham GS, Amass L, Winhusen T, et al. Using buprenorphine shortterm taper to facilitate early treatment engagement. J Subst Abuse Treat. 2007;32:349-356.
21. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag; 1991.
22. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365-374.
23. Sees KL, Delucci KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283:1303-1310.
24. Hser YI, Hoffman V, Grella CE, et al. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2000;58:503-508.
25. Center for Substance Abuse Treatment (CSAT).Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939.
26. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
27. Doran C, Holmes J, Ladewig D, et al. Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addict Rel Clin Problems. 2005;7:7-18.
28. Sullivan LE, Chawarski M, O'Connor PG, et al. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering treatment? Drug Alcohol Depend. 2005;79:113-116.
29. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
30. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1995-1996.